Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 8/20 | 0.45 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768924 | 1.00 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DCNR1 | |
| SCHEMBL5769821 | 0.91 | CNR1 (0.50) | CNR1FAAHCNR2OPRL1 | |
| SCHEMBL5769885 | 0.91 | CNR1 (0.48) | CNR1CNR2OPRL1 | |
| SCHEMBL6766010 | 0.91 | CNR1 (0.48) | CNR1CNR2OPRL1 | |
| SCHEMBL5767881 | 0.88 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5768237 | 0.87 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5768407 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL6765658 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL5767412 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL5768236 | 0.87 | CNR1 (0.49) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | claimed |
| EP-1622876-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004099157-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | PDE4B 2564/4885PDE4A 2454/4885PDE4C 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.